多肽CRDMO平台
目录肽
中肽生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
HITM-002B
Intermedin (rat)
Pro-His-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Val-Arg-Pro-Ser-Gly-Arg-Arg-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2\n(Disulfide bond Cys10-Cys15) \nTrifluoroacetate salt
Pro-His-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Val-Arg-Pro-Ser-Gly-Arg-Arg-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2\n(Disulfide bond Cys10-Cys15) \nTrifluoroacetate salt
Size：1
P1(RMB)：1750
MW：5216.95
One letter sequence：PHAQLLRVGCVLGTCQVQNLSHRLWQLVRPSGRRDSAPVDPSSPHSY-NH2
Molecular Formula：C226H361N75O64S2
Description：Intermedins are members of the calcitonin/CGRP family. In vitro studies have shown that the synthetic 47 amino acid intermedin peptides act through the calcitonin receptor-like receptor/receptor activity-modifying protein (CRLR/RAMP) complexes by increasing intracellular cAMP levels. Unlike calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM) intermedin exhibited no preference for one of the three RAMPs when co-expressed with CRLR.\nIn normal and spontaneously hypertensive rats it has been demonstrated that intermedin treatment results in blood pressure reduction which can be blocked by the CGRP receptor antagonist CGRP (8-37). Apart from the hypotensive action, synthetic intermedin has also been shown to inhibit gastric emptying and food intake in mice.\nTherefore, intermedin represents an additional regulator of gastrointestinal and cardiovascular functions and might be involved in other bioactivities mediated by the CRLR/RAMP receptor complexes.
Literature Reference：Y.Fujisawa et al., Am. J. Physiol. Heart Circ. Physiol., 290, H1120 (2006)\nM.Chauhan et al., Endocrinology, 148, 1727 (2007)\nM. Ogoshi et al.,Biochem. Biophys. Res. Commun., 311, 1072 (2003).\nY. Takei et al.,FEBS Lett., 556, 53 (2004).\nJ. Roh et al., J. Biol. Chem., 279, 7264 (2004)\nY. Fujisawa et al., Eur. J. Pharmacol., 497, 75 (2004). \nM.M. Taylor et al.,Integr. Comp. Physiol., 288, R919 (2005).\nK. Takahashi et al.,Peptides, 27, 1 383 (2006)\nD. Bell et al., J. Pharmacol., 153, S247 (2008)
Cas：
P1(RMB)：1750
MW：5216.95
One letter sequence：PHAQLLRVGCVLGTCQVQNLSHRLWQLVRPSGRRDSAPVDPSSPHSY-NH2
Molecular Formula：C226H361N75O64S2
Description：Intermedins are members of the calcitonin/CGRP family. In vitro studies have shown that the synthetic 47 amino acid intermedin peptides act through the calcitonin receptor-like receptor/receptor activity-modifying protein (CRLR/RAMP) complexes by increasing intracellular cAMP levels. Unlike calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM) intermedin exhibited no preference for one of the three RAMPs when co-expressed with CRLR.\nIn normal and spontaneously hypertensive rats it has been demonstrated that intermedin treatment results in blood pressure reduction which can be blocked by the CGRP receptor antagonist CGRP (8-37). Apart from the hypotensive action, synthetic intermedin has also been shown to inhibit gastric emptying and food intake in mice.\nTherefore, intermedin represents an additional regulator of gastrointestinal and cardiovascular functions and might be involved in other bioactivities mediated by the CRLR/RAMP receptor complexes.
Literature Reference：Y.Fujisawa et al., Am. J. Physiol. Heart Circ. Physiol., 290, H1120 (2006)\nM.Chauhan et al., Endocrinology, 148, 1727 (2007)\nM. Ogoshi et al.,Biochem. Biophys. Res. Commun., 311, 1072 (2003).\nY. Takei et al.,FEBS Lett., 556, 53 (2004).\nJ. Roh et al., J. Biol. Chem., 279, 7264 (2004)\nY. Fujisawa et al., Eur. J. Pharmacol., 497, 75 (2004). \nM.M. Taylor et al.,Integr. Comp. Physiol., 288, R919 (2005).\nK. Takahashi et al.,Peptides, 27, 1 383 (2006)\nD. Bell et al., J. Pharmacol., 153, S247 (2008)
Cas：
